Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Immunology | Musculoskeletal | Rheumatology | Family Medicine
Search Medical Condition
Rheumatoid Arthritis Clinical Trials
A listing of Rheumatoid Arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (393) clinical trials
Discovering the antecedents of rheumatoid arthritis flare.
Patients with rheumatoid arthritis can develop unpredictable worsening of their disease (flare) that is extraordinarily painful and limits ability to function. Flares are often preceded by early warnings of fatigue and flu-like symptoms. It is not known how long these early warning symptoms last or what causes them. It is ...
A multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren’s syndrome
Winthrop University Hospital Clinical Trials Center in conjunction with The Division of Rheumatology and The Arthritis and Rheumatic Disease Center is conducting a clinical research study on an investigational medication, for patient with dry mouth associated with SjÖgren’s Syndrome. This study will evaluate the safety and effectiveness of an investigational ...
FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
FINCH 1 is enrolling RA patients who have taken methotrexate (also known as MTX, TREXALL, or RASUVO) but have not yet tried a biologic treatment. Filgotinib (study drug) is an oral medication designed to reduce joint inflammation.
FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
FINCH 1 is enrolling RA patients, who have taken methotrexate (also known as; MTX, TrexaIl® or Rasuvo®) but have not yet tried a biologic treatment.
CREDO 2: A Randomized, Double Blind, Parallel Group, Placebo and Active Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy CREDO 3: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy
The purpose of this study is to determine the effectiveness of the investigational drug Olokizumab in patients living with Rheumatoid Arthritis (RA).
Rheumatoid arthritis can affect your daily life, don't let it win! Learn more about a new research study now enrolling.
Rheumatoid Arthritis is a chronic immune/inflammatory disease characterized by persistent synovitis. If you have a diagnosis of rheumatoid arthritis, a clinical research study could be an option for you. New England Research is currently conducting a study to test the safety and effectiveness of the the drug Olokizumab in patients ...
12 Month to assess the clinical and economic outcomes of Vectra DA guided treatment compared with usual care in subject with Rheumatoid Arthritis with inadequate response to MTX
Adults with Rheumatoid Arthritis with inadequate response to MTX may qualify to have Vectra DA guided treatment for 12 months.
A Phase III study of the Efficacy and Safety of subjects with Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor therapy
Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor therapy
A Phase 3, Randomized, Double-Blind Study comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Participation in this research study would last approximately 24 weeks and would include at least 11 visits to our office. Compensation up to $75 per visit may be provided for time and travel.
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate.
